12938083	207	Eng C	PTEN: one gene, many syndromes.	Human mutation	2003	184
16715125	207	Wang X	Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation.	Oncogene	2006	71
17611497	207	Carpten JD	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.	Nature	2007	373
18504432	207	Bleeker FE	AKT1(E17K) in human solid tumours.	Oncogene	2008	55
18676830	207	Stemke-Hale K	An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.	Cancer research	2008	299
19380449	207	Baselga J	Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2009	138
19411071	207	Junttila TT	Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.	Cancer cell	2009	221
19491896	207	Shoji K	The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.	British journal of cancer	2009	51
21216929	207	Janku F	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.	Molecular cancer therapeutics	2011	127
22422409	207	Meric-Bernstam F	PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.	Clinical cancer research 	2012	61
22932669	207	Sangai T	Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.	Clinical cancer research 	2012	44
25071141	207	Sabine VS	Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.	Journal of clinical oncology 	2014	21
25185240	207	Roth√© F	Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.	Annals of oncology 	2014	35
25284585	207	Dillon LM	P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.	Oncogene	2015	17
26473415	207	Mayer IA	The PI3K/AKT Pathway as a Target for Cancer Treatment.	Annual review of medicine	2016	38
27184417	367	Bianchini G	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.	Nature reviews. Clinical oncology	2016	42
15928302	472	Thompson D	Cancer risks and mortality in heterozygous ATM mutation carriers.	Journal of the National Cancer Institute	2005	85
11301010	571	Cantor SB	BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.	Cell	2001	199
15125843	571	Shiozaki EN	Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.	Molecular cell	2004	75
19088202	580	Reid LJ	E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.	Proceedings of the National Academy of Sciences of the United States of America	2008	53
25452441	580	Couch FJ	Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.	Journal of clinical oncology 	2015	60
8137296	595	Gillett C	Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.	Cancer research	1994	129
7907678	672	Ford D	Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.	Lancet	1994	261
9145676	672	Struewing JP	The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.	The New England journal of medicine	1997	316
9443863	672	Parmigiani G	Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.	American journal of human genetics	1998	141
9701363	672	Lakhani SR	Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.	Journal of the National Cancer Institute	1998	119
10359546	672	Peto J	Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.	Journal of the National Cancer Institute	1999	148
11179017	672	Risch HA	Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.	American journal of human genetics	2001	166
11207349	672	Hedenfalk I	Gene-expression profiles in hereditary breast cancer.	The New England journal of medicine	2001	260
11257103	672	Welcsh PL	BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.	Human molecular genetics	2001	114
11320250	672	Ruffner H	Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.	Proceedings of the National Academy of Sciences of the United States of America	2001	96
11463009	672	Meijers-Heijboer H	Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.	The New England journal of medicine	2001	91
11710890	672	King MC	Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.	JAMA	2001	91
11857015	672	Antoniou AC	A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.	British journal of cancer	2002	106
12023992	672	Kauff ND	Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.	The New England journal of medicine	2002	167
12023993	672	Rebbeck TR	Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.	The New England journal of medicine	2002	204
12162889	672	Radmacher MD	A paradigm for class prediction using gene expression profiles.	Journal of computational biology 	2002	82
12237281	672	Thompson D	Cancer Incidence in BRCA1 mutation carriers.	Journal of the National Cancer Institute	2002	206
12483514	672	Jasin M	Homologous repair of DNA damage and tumorigenesis: the BRCA connection.	Oncogene	2002	94
12677558	672	Antoniou A	Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.	American journal of human genetics	2003	579
14576434	672	King MC	Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.	Science	2003	394
14981104	672	Rebbeck TR	Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.	Journal of clinical oncology 	2004	146
15041722	672	Foulkes WD	Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.	Clinical cancer research 	2004	76
15197194	672	Metcalfe K	Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2004	111
15367553	672	Warner E	Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.	JAMA	2004	146
15547178	672	Kennedy RD	The role of BRCA1 in the cellular response to chemotherapy.	Journal of the National Cancer Institute	2004	85
15784178	672	Dumitrescu RG	Understanding breast cancer risk -- where do we stand in 2005?	Journal of cellular and molecular medicine	2005	81
15910949	672	Leach MO	Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).	Lancet	2005	156
16014699	672	Tavtigian SV	Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.	Journal of medical genetics	2006	168
16144895	672	Nelson HD	Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.	Annals of internal medicine	2005	84
16234515	672	Eisen A	Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.	Journal of clinical oncology 	2005	79
16284991	672	Pal T	BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.	Cancer	2005	156
16293877	672	Kuhl CK	Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.	Journal of clinical oncology 	2005	116
16397213	672	Elstrodt F	BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.	Cancer research	2006	68
16484695	672	Chen S	Characterization of BRCA1 and BRCA2 mutations in a large United States sample.	Journal of clinical oncology 	2006	70
16522651	672	Deng CX	BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.	Nucleic acids research	2006	120
16912212	672	Malone KE	Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.	Cancer research	2006	64
17148771	672	Risch HA	Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.	Journal of the National Cancer Institute	2006	127
17416853	672	Chen S	Meta-analysis of BRCA1 and BRCA2 penetrance.	Journal of clinical oncology 	2007	280
17924331	672	Easton DF	A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.	American journal of human genetics	2007	131
18034184	672	Fackenthal JD	Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.	Nature reviews. Cancer	2007	108
18159056	672	John EM	Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.	JAMA	2007	104
18182601	672	Begg CB	Variation of breast cancer risk among BRCA1/2 carriers.	JAMA	2008	82
18268356	672	Kauff ND	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.	Journal of clinical oncology 	2008	92
18349832	672	Antoniou AC	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.	British journal of cancer	2008	99
18458280	672	Warner E	Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer.	Annals of internal medicine	2008	79
18649131	672	Byrski T	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2009	72
18779615	672	Atchley DP	Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.	Journal of clinical oncology 	2008	107
18955455	672	Tan DS	"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.	Journal of clinical oncology 	2008	101
19141781	672	Rebbeck TR	Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.	Journal of the National Cancer Institute	2009	128
19241424	672	Hall MJ	BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.	Cancer	2009	70
19298662	672	Young SR	The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.	BMC cancer	2009	55
19553641	672	Fong PC	Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.	The New England journal of medicine	2009	840
19648928	672	Lim E	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.	Nature medicine	2009	454
19841585	672	Kurian AW	BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications.	Current opinion in obstetrics and gynecology	2010	41
19858402	672	Graeser MK	Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2009	52
19996028	672	Oktay K	Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.	Journal of clinical oncology 	2010	57
20008645	672	Byrski T	Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.	Journal of clinical oncology 	2010	108
20368571	672	Malone KE	Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.	Journal of clinical oncology 	2010	46
20400477	672	O'Donovan PJ	BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.	Carcinogenesis	2010	70
20427433	672	Amir E	Assessing women at high risk of breast cancer: a review of risk assessment models.	Journal of the National Cancer Institute	2010	89
20516115	672	Lee MS	Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.	Cancer research	2010	40
20609467	672	Tutt A	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.	Lancet	2010	389
20616022	672	Walsh T	Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2010	126
20810374	672	Domchek SM	Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.	JAMA	2010	187
21233401	672	Gonzalez-Angulo AM	Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.	Clinical cancer research 	2011	109
21324516	672	Zhang S	Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.	Gynecologic oncology	2011	52
21358336	672	Levy DE	Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk.	Genetics in medicine 	2011	55
21505135	672	Link DC	Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.	JAMA	2011	59
21717445	672	Schwartz MD	Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.	Cancer	2012	31
21987798	672	Konishi H	Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	47
21990146	672	Spurdle AB	ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.	Human mutation	2012	45
22193408	672	Roy R	BRCA1 and BRCA2: different roles in a common pathway of genome protection.	Nature reviews. Cancer	2011	216
22314128	672	Krepischi AC	Germline DNA copy number variation in familial and early-onset breast cancer.	Breast cancer research 	2012	31
22516946	672	Leongamornlert D	Germline BRCA1 mutations increase prostate cancer risk.	British journal of cancer	2012	30
22576213	672	Birkbak NJ	Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.	Cancer discovery	2012	44
22614657	672	Hartman AR	Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.	Cancer	2012	37
22933060	672	Popova T	Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.	Cancer research	2012	57
23099806	672	Iqbal J	The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.	British journal of cancer	2012	33
23233716	672	Weitzel JN	Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.	Journal of clinical oncology 	2013	33
23269703	672	Domchek SM	Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.	Cancer discovery	2013	29
23558900	672	Lips EH	Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.	British journal of cancer	2013	33
23628597	672	Mavaddat N	Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.	Journal of the National Cancer Institute	2013	94
23810788	672	Sandhu SK	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.	The Lancet. Oncology	2013	84
23918944	672	Phillips KA	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2013	27
23942203	672	Tarabeux J	Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model.	European journal of human genetics 	2014	21
24042365	672	Rosenberg SM	Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.	Annals of internal medicine	2013	27
24140203	672	Widschwendter M	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.	The Lancet. Oncology	2013	25
24225019	672	Lee JM	PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.	Annals of oncology 	2014	55
24292448	672	Phelan CM	Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.	British journal of cancer	2014	23
24346285	672	Lee AJ	BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.	British journal of cancer	2014	21
24366376	672	Moyer VA	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.	Annals of internal medicine	2014	57
24366442	672	Nelson HD	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.	Annals of internal medicine	2014	33
24449235	672	Schwartz MD	Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.	Journal of clinical oncology 	2014	24
24478461	672	Laddha SV	Mutational landscape of the essential autophagy gene BECN1 in human cancers.	Molecular cancer research 	2014	37
24519767	672	Metcalfe K	Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.	BMJ	2014	23
24618965	672	Dewey FE	Clinical interpretation and implications of whole-genome sequencing.	JAMA	2014	118
24675953	672	Couch FJ	Two decades after BRCA: setting paradigms in personalized cancer care and prevention.	Science	2014	57
24675954	672	Venkitaraman AR	Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.	Science	2014	31
24824314	672	Friebel TM	Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.	Journal of the National Cancer Institute	2014	23
24947112	672	Heemskerk-Gerritsen BA	Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.	International journal of cancer	2015	16
25224030	672	Mersch J	Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.	Cancer	2015	25
25348513	672	Zhong Q	Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.	Clinical cancer research 	2015	19
25366685	672	Kaufman B	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.	Journal of clinical oncology 	2015	144
25398451	672	Candido-dos-Reis FJ	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.	Clinical cancer research 	2015	16
25673085	672	Dietze EC	Triple-negative breast cancer in African-American women: disparities versus biology.	Nature reviews. Cancer	2015	28
26426480	672	Armstrong J	Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.	JAMA oncology	2015	15
26757170	672	Siu AL	Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement.	Annals of internal medicine	2016	42
8524414	675	Wooster R	Identification of the breast cancer susceptibility gene BRCA2.	Nature	1995	496
8589730	675	Tavtigian SV	The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.	Nature genetics	1996	133
8968085	675	Goggins M	Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.	Cancer research	1996	133
10433620	675	Breast Cancer Linkage Consortium.	Cancer risks in BRCA2 mutation carriers.	Journal of the National Cancer Institute	1999	251
16141007	675	van Asperen CJ	Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.	Journal of medical genetics	2005	70
16793542	675	Xia B	Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.	Molecular cell	2006	233
23165508	675	Barber LJ	Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.	The Journal of pathology	2013	40
23544012	675	Gaudet MM	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk.	PLoS genetics	2013	45
8557030	999	Berx G	E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers.	The EMBO journal	1995	152
11597316	999	Berx G	The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression.	Breast cancer research 	2001	92
16495925	999	Lombaerts M	E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines.	British journal of cancer	2006	104
17545690	999	Kaurah P	Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer.	JAMA	2007	66
20591882	999	Fitzgerald RC	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research.	Journal of medical genetics	2010	71
25979631	999	van der Post RS	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.	Journal of medical genetics	2015	26
10499591	1017	Spruck CH	Deregulated cyclin E induces chromosome instability.	Nature	1999	188
12124352	1017	Yakes FM	Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.	Cancer research	2002	158
21321214	1017	Scaltriti M	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2011	79
25002028	1019	Vora SR	CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.	Cancer cell	2014	50
26947331	1019	Cristofanilli M	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.	The Lancet. Oncology	2016	40
9296497	1026	Somasundaram K	Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.	Nature	1997	106
16854453	1026	McCubrey JA	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.	Advances in enzyme regulation	2006	155
9018243	1027	Porter PL	Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.	Nature medicine	1997	135
7553621	1029	Herman JG	Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.	Cancer research	1995	241
8153634	1029	Kamb A	A cell cycle regulator potentially involved in genesis of many tumor types.	Science	1994	337
17334996	1029	J√∂nsson G	High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.	Genes, chromosomes and cancer	2007	64
19593635	1029	Hollestelle A	Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.	Breast cancer research and treatment	2010	83
23601657	1029	Riaz M	miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.	Breast cancer research 	2013	38
24733792	1029	Kurian AW	Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.	Journal of clinical oncology 	2014	68
25009010	1029	De Mattos-Arruda L	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.	Annals of oncology 	2014	47
25479140	1029	Grant RC	Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.	Gastroenterology	2015	23
25503501	1029	Maxwell KN	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.	Genetics in medicine 	2015	24
12781359	1111	Bartek J	Chk1 and Chk2 kinases in checkpoint control and cancer.	Cancer cell	2003	347
23242585	1111	Ma CX	A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.	Breast cancer research and treatment	2013	27
20007781	1302	Brachmann SM	Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	105
24270682	1302	Bouwman P	Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?	Clinical cancer research 	2014	40
20393555	1495	Ding L	Genome remodelling in a basal-like breast cancer metastasis and xenograft.	Nature	2010	417
26182300	1495	Hansford S	Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.	JAMA oncology	2015	23
11940574	1499	Leung JY	Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling.	The Journal of biological chemistry	2002	119
17295177	1499	Villanueva A	Genomics and signaling pathways in hepatocellular carcinoma.	Seminars in liver disease	2007	150
21076461	1499	Geyer FC	Œ≤-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.	Modern pathology 	2011	81
22538770	1499	Santarpia L	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.	Breast cancer research and treatment	2012	35
23636398	1499	Cancer Genome Atlas Research Network.	Integrated genomic characterization of endometrial carcinoma.	Nature	2013	552
22395643	1565	Rae JM	CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.	Journal of the National Cancer Institute	2012	59
25907219	1588	Ma CX	Mechanisms of aromatase inhibitor resistance.	Nature reviews. Cancer	2015	34
3798106	1956	Slamon DJ	Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.	Science	1987	1881
15057284	1956	Qian X	E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.	The EMBO journal	2004	106
15158434	1956	Roskoski R Jr	The ErbB/HER receptor protein-tyrosine kinases and cancer.	Biochemical and biophysical research communications	2004	70
15753357	1956	Shigematsu H	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.	Cancer research	2005	142
15920544	1956	Bhargava R	EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.	Modern pathology 	2005	76
16033833	1956	Lakhani SR	Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.	Clinical cancer research 	2005	149
16757721	1956	Carey LA	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.	JAMA	2006	957
17126425	1956	McCubrey JA	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.	Biochimica et biophysica acta	2007	423
17218988	1956	Kenny PA	Targeting TACE-dependent EGFR ligand shedding in breast cancer.	The Journal of clinical investigation	2007	72
17283074	1956	Hsu SC	Characterization of a novel tripartite nuclear localization sequence in the EGFR family.	The Journal of biological chemistry	2007	83
18060032	1956	Gao SP	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.	The Journal of clinical investigation	2007	193
19596646	1956	Anders CK	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.	Clinical breast cancer	2009	104
20351699	1956	Harris TJ	The molecular pathology of cancer.	Nature reviews. Clinical oncology	2010	57
20838621	1956	Punnoose EA	Molecular biomarker analyses using circulating tumor cells.	PloS one	2010	78
21687663	1956	Li N	Inhibition of cell proliferation by an anti-EGFR aptamer.	PloS one	2011	41
22189713	1956	Deng XS	Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.	Cell cycle	2012	48
22209049	1956	O'Flaherty JD	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.	Lung cancer	2012	44
22649089	1956	Forshew T	Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.	Science translational medicine	2012	209
22956860	1956	Creighton CJ	The molecular profile of luminal B breast cancer.	Biologics 	2012	45
23000897	1956	Cancer Genome Atlas Network.	Comprehensive molecular portraits of human breast tumours.	Nature	2012	2327
23012302	1956	Andr√© F	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.	Annals of oncology 	2012	58
23563269	1956	Murtaza M	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.	Nature	2013	259
24269963	1956	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	122
24384534	1956	Maroun CR	The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.	Pharmacology and therapeutics	2014	31
24406864	1956	Park HS	High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.	Modern pathology 	2014	33
24656976	1956	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	40
25137181	1956	Marchetti A	Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.	PloS one	2014	33
25593300	1956	Cani AK	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.	Molecular cancer research 	2015	18
26690310	1956	Richman SD	HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.	The Journal of pathology	2016	11
26926684	1956	Desmedt C	Genomic Characterization of Primary Invasive Lobular Breast Cancer.	Journal of clinical oncology 	2016	12
21876152	1977	Ilic N	PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.	Proceedings of the National Academy of Sciences of the United States of America	2011	78
24842883	1977	Lee JM	Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.	Journal of the National Cancer Institute	2014	40
2470152	2064	Slamon DJ	Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.	Science	1989	1073
7657393	2064	Bellacosa A	Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.	International journal of cancer	1995	174
11694782	2064	Yarden Y	Biology of HER2 and its importance in breast cancer.	Oncology	2001	104
12761490	2064	Knuefermann C	HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.	Oncogene	2003	102
15194824	2064	Meng S	HER-2 gene amplification can be acquired as breast cancer progresses.	Proceedings of the National Academy of Sciences of the United States of America	2004	119
16707747	2064	Pritchard KI	HER2 and responsiveness of breast cancer to adjuvant chemotherapy.	The New England journal of medicine	2006	100
16846532	2064	Calza S	Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients.	Breast cancer research 	2006	81
16868827	2064	Park DI	HER-2/neu amplification is an independent prognostic factor in gastric cancer.	Digestive diseases and sciences	2006	70
17157792	2064	Chin K	Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.	Cancer cell	2006	472
17377838	2064	Soerjomataram I	An overview of prognostic factors for long-term survivors of breast cancer.	Breast cancer research and treatment	2008	84
17440164	2064	Scaltriti M	Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.	Journal of the National Cancer Institute	2007	170
17471238	2064	Moasser MM	The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.	Oncogene	2007	133
17606733	2064	Marangoni E	A new model of patient tumor-derived breast cancer xenografts for preclinical assays.	Clinical cancer research 	2007	106
17686164	2064	Viani GA	Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.	BMC cancer	2007	74
18171422	2064	Reis-Filho JS	Triple negative tumours: a critical review.	Histopathology	2008	212
18223211	2064	Allred DC	Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.	Clinical cancer research 	2008	91
18339869	2064	Yamaguchi N	NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells.	Cancer research	2008	54
18434311	2064	Najy AJ	The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.	The Journal of biological chemistry	2008	61
18487574	2064	Rakha EA	Basal-like breast cancer: a critical review.	Journal of clinical oncology 	2008	213
18625725	2064	Wang SE	Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.	Molecular and cellular biology	2008	61
18829560	2064	Serra V	NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.	Cancer research	2008	251
19008097	2064	Irvin WJ Jr	What is triple-negative breast cancer?	European journal of cancer	2008	77
19010894	2064	Eichhorn PJ	Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.	Cancer research	2008	140
19204209	2064	Sauter G	Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.	Journal of clinical oncology 	2009	106
19318578	2064	Neal CL	14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival.	Cancer research	2009	55
19597704	2064	Pestrin M	Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.	Breast cancer research and treatment	2009	56
19633047	2064	Kataoka Y	Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.	Annals of oncology 	2010	56
19766563	2064	Cicalese A	The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells.	Cell	2009	231
20100965	2064	Silver DP	Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.	Journal of clinical oncology 	2010	209
20231686	2064	Staaf J	Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.	Journal of clinical oncology 	2010	54
20453058	2064	O'Brien C	Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.	Clinical cancer research 	2010	82
20576095	2064	J√∂nsson G	Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.	Breast cancer research 	2010	65
20581867	2064	Chakrabarty A	H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.	Oncogene	2010	43
20877296	2064	Carey L	Triple-negative breast cancer: disease entity or title of convenience?	Nature reviews. Clinical oncology	2010	180
20920229	2064	Bediaga NG	DNA methylation epigenotypes in breast cancer molecular subtypes.	Breast cancer research 	2010	47
21050424	2064	Chac√≥n RD	Triple-negative breast cancer.	Breast cancer research 	2010	57
21115860	2064	Valero V	Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.	Journal of clinical oncology 	2011	43
21135276	2064	Dave B	Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.	Journal of clinical oncology 	2011	77
21373875	2064	Gl√ºck S	TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ¬± trastuzumab.	Breast cancer research and treatment	2012	58
21965336	2064	Higgins MJ	Targeted therapies for breast cancer.	The Journal of clinical investigation	2011	89
22114931	2064	Miller TW	Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.	Breast cancer research 	2011	84
22124364	2064	Arteaga CL	Treatment of HER2-positive breast cancer: current status and future perspectives.	Nature reviews. Clinical oncology	2011	196
22172323	2064	Jensen JD	PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.	Annals of oncology 	2012	36
22198468	2064	Esserman LJ	Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).	Breast cancer research and treatment	2012	88
22331459	2064	Stevens KN	19p13.1 is a triple-negative-specific breast cancer susceptibility locus.	Cancer research	2012	44
22373922	2064	Whale AS	Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation.	Nucleic acids research	2012	57
22388760	2064	Seol H	Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.	Modern pathology 	2012	36
22471661	2064	Rexer BN	Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.	Critical reviews in oncogenesis	2012	67
22495314	2064	Shah SP	The clonal and mutational evolution spectrum of primary triple-negative breast cancers.	Nature	2012	499
22817698	2064	Byrski T	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.	Breast cancer research 	2012	36
23220880	2064	Bose R	Activating HER2 mutations in HER2 gene amplification negative breast cancer.	Cancer discovery	2013	135
23442322	2064	Ithimakin S	HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.	Cancer research	2013	55
23589555	2064	Sleijfer S	Designing transformative clinical trials in the cancer genome era.	Journal of clinical oncology 	2013	35
23807776	2064	Hanna WM	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.	Modern pathology 	2014	31
23852170	2064	Roberts SA	An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.	Nature genetics	2013	205
24323026	2064	Gandhi L	Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.	Journal of clinical oncology 	2014	37
24739973	2064	Godinho SA	Oncogene-like induction of cellular invasion from centrosome amplification.	Nature	2014	60
24829859	2064	Yadav BS	Systemic treatment strategies for triple-negative breast cancer.	World journal of clinical oncology	2014	24
24960601	2064	Choi W	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.	Nature reviews. Urology	2014	30
24970867	2064	Wilkerson MD	Integrated RNA and DNA sequencing improves mutation detection in low purity tumors.	Nucleic acids research	2014	21
25129345	2064	Byrski T	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2014	31
25332247	2064	Baselga J	Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.	Journal of clinical oncology 	2014	42
25559818	2064	Majewski IJ	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.	Journal of clinical oncology 	2015	38
25682074	2064	Wong-Brown MW	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.	Breast cancer research and treatment	2015	17
25713166	2064	Ng CK	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.	Journal of the National Cancer Institute	2015	20
25805799	2064	Basu B	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.	Clinical cancer research 	2015	21
25847929	2064	Telli ML	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.	Journal of clinical oncology 	2015	27
25902832	2064	Toss A	Molecular characterization and targeted therapeutic approaches in breast cancer.	Breast cancer research 	2015	19
26387133	2064	Palma G	Triple negative breast cancer: looking for the missing link between biology and treatments.	Oncotarget	2015	25
26527775	2064	Carey LA	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.	Journal of clinical oncology 	2016	16
26530965	2064	Murtaza M	Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.	Nature communications	2015	33
26995633	2064	Yang SX	New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.	Cancer treatment reviews	2016	15
27269946	2064	Fribbens C	Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.	Journal of clinical oncology 	2016	25
19435893	2065	Miller TW	Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.	Cancer research	2009	55
23680147	2065	Jaiswal BS	Oncogenic ERBB3 mutations in human cancers.	Cancer cell	2013	69
25583476	2066	Chen K	Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy.	Proceedings of the National Academy of Sciences of the United States of America	2015	22
7641693	2099	Cavaill√®s V	Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.	The EMBO journal	1995	165
9524123	2099	Migliaccio A	Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.	The EMBO journal	1998	119
15583021	2099	Herynk MH	Estrogen receptor mutations in human disease.	Endocrine reviews	2004	78
16897746	2099	Bergamaschi A	Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.	Genes, chromosomes and cancer	2006	161
17113977	2099	Russo J	The role of estrogen in the initiation of breast cancer.	The Journal of steroid biochemistry and molecular biology	2006	72
17417639	2099	Holst F	Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.	Nature genetics	2007	75
18574464	2099	Ramsay RG	MYB function in normal and cancer cells.	Nature reviews. Cancer	2008	146
20180843	2099	Xiong J	An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples.	The FEBS journal	2010	45
20427689	2099	Barone I	Estrogen receptor mutations and changes in downstream gene expression and signaling.	Clinical cancer research 	2010	42
20547749	2099	Stender JD	Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation.	Molecular and cellular biology	2010	63
21362200	2099	Sanchez CG	Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.	Breast cancer research 	2011	46
24055055	2099	Li S	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.	Cell reports	2013	117
24185510	2099	Robinson DR	Activating ESR1 mutations in hormone-resistant metastatic breast cancer.	Nature genetics	2013	157
24217577	2099	Merenbakh-Lamin K	D538G mutation in estrogen receptor-Œ±: A novel mechanism for acquired endocrine resistance in breast cancer.	Cancer research	2013	56
24398047	2099	Jeselsohn R	Emergence of constitutively active estrogen receptor-Œ± mutations in pretreated advanced estrogen receptor-positive breast cancer.	Clinical cancer research 	2014	76
24663045	2099	Mayer IA	Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2014	41
24858917	2099	Ohba K	In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction.	PloS one	2014	23
25013076	2099	Yu M	Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.	Science	2014	133
25877889	2099	Bosch A	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.	Science translational medicine	2015	28
25979954	2099	Guttery DS	Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.	Clinical chemistry	2015	22
26261103	2099	Chu D	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.	Clinical cancer research 	2016	22
26317216	2099	Butler TM	Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease.	PloS one	2015	17
26500237	2099	Wang P	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.	Clinical cancer research 	2016	22
26560360	2099	Schiavon G	Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.	Science translational medicine	2015	41
26563128	2099	Ma CX	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.	Clinical cancer research 	2016	13
27532364	2099	Chandarlapaty S	Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.	JAMA oncology	2016	18
20410810	2120	Sk√°lov√° A	Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.	The American journal of surgical pathology	2010	69
21367748	2146	Chase A	Aberrations of EZH2 in cancer.	Clinical cancer research 	2011	141
26085575	2177	Virts EL	AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia.	Human molecular genetics	2015	19
27208205	2177	Park JY	Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene.	Journal of medical genetics	2016	16
23658459	2248	Andr√© F	Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.	Clinical cancer research 	2013	55
24265351	2248	Dienstmann R	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.	Annals of oncology 	2014	51
26373574	2260	Helsten T	The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.	Clinical cancer research 	2016	21
18636142	2263	Katoh M	Cancer genomics and genetics of FGFR2 (Review).	International journal of oncology	2008	50
15254063	2475	Sansal I	The biology and clinical relevance of the PTEN tumor suppressor pathway.	Journal of clinical oncology 	2004	215
17599906	2475	Woo SY	PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.	The Journal of biological chemistry	2007	75
18787170	2475	Mao JH	FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.	Science	2008	130
20479250	2475	Loi S	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	106
21946274	2475	Muellner MK	A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.	Nature chemical biology	2011	50
21998291	2475	Wallin JJ	GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.	Molecular cancer therapeutics	2011	64
23012305	2475	Crown J	Emerging targeted therapies in triple-negative breast cancer.	Annals of oncology 	2012	47
25103565	2475	Lehmann BD	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.	Breast cancer research 	2014	32
15361840	2625	Usary J	Mutation of GATA3 in human breast tumors.	Oncogene	2004	75
22331944	2956	Win AK	Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.	Journal of clinical oncology 	2012	68
23091106	2956	Engel C	Risks of less common cancers in proven mutation carriers with lynch syndrome.	Journal of clinical oncology 	2012	32
25238946	2956	Lancaster JM	Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.	Gynecologic oncology	2015	24
26880610	2956	Dudley JC	Microsatellite Instability as a Biomarker for PD-1 Blockade.	Clinical cancer research 	2016	28
17142309	3164	Hicks J	Novel patterns of genome rearrangement and their association with survival in breast cancer.	Genome research	2006	113
24695311	3265	Cleary AS	Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers.	Nature	2014	71
19378339	3417	Kang MR	Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.	International journal of cancer	2009	86
25091696	3417	Tang X	A joint analysis of metabolomics and genetics of breast cancer.	Breast cancer research 	2014	26
20505728	3845	Lee W	The mutation spectrum revealed by paired genome sequences from a lung cancer patient.	Nature	2010	197
21435948	3845	Paranjape T	A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.	The Lancet. Oncology	2011	44
23792451	3845	Ogino S	Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.	Oncogene	2014	38
26085511	3845	Frenel JS	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.	Clinical cancer research 	2015	31
18398828	4292	Watson P	The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.	International journal of cancer	2008	95
23484797	4582	Dawson SJ	Analysis of circulating tumor DNA to monitor metastatic breast cancer.	The New England journal of medicine	2013	320
17908964	4609	Guan Y	Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.	Clinical cancer research 	2007	98
26099045	4609	Yates LR	Subclonal diversification of primary breast cancer revealed by multiregion sequencing.	Nature medicine	2015	74
9590180	4683	Varon R	Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome.	Cell	1998	181
23468639	4683	Wang H	The interaction of CtIP and Nbs1 connects CDK and ATM to regulate HR-mediated double-strand break repair.	PLoS genetics	2013	42
15016963	5290	Samuels Y	High frequency of mutations of the PIK3CA gene in human cancers.	Science	2004	909
15254419	5290	Bachman KE	The PIK3CA gene is mutated with high frequency in human breast cancers.	Cancer biology and therapy	2004	179
15467468	5290	Samuels Y	Oncogenic mutations of PIK3CA in human cancers.	Cell cycle	2004	125
15520168	5290	Campbell IG	Mutation of the PIK3CA gene in ovarian and breast cancer.	Cancer research	2004	221
15608678	5290	Lee JW	PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.	Oncogene	2005	111
15805248	5290	Saal LH	PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.	Cancer research	2005	253
16288007	5290	Garc√≠a-Rost√°n G	Mutation of the PIK3CA gene in anaplastic thyroid cancer.	Cancer research	2005	81
16322248	5290	Isakoff SJ	Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.	Cancer research	2005	167
17314276	5290	Hollestelle A	Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.	Molecular cancer research 	2007	106
17575221	5290	P√©rez-Tenorio G	PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.	Clinical cancer research 	2007	91
17936563	5290	Berns K	A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.	Cancer cell	2007	406
19276248	5290	Gonzalez-Angulo AM	Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.	Clinical cancer research 	2009	67
19573809	5290	Vasudevan KM	AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.	Cancer cell	2009	179
19671852	5290	Kalinsky K	PIK3CA mutation associates with improved outcome in breast cancer.	Clinical cancer research 	2009	102
19685490	5290	L√≥pez-Knowles E	PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.	International journal of cancer	2010	65
20813970	5290	Esteva FJ	PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.	The American journal of pathology	2010	94
20940279	5290	Dupont Jensen J	PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer.	Clinical cancer research 	2011	54
21358673	5290	Weigelt B	PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.	Oncogene	2011	65
21482677	5290	Meyer DS	Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.	Cancer research	2011	40
21490305	5290	Gonzalez-Angulo AM	PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.	Molecular cancer therapeutics	2011	71
21594665	5290	Razis E	Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.	Breast cancer research and treatment	2011	67
21676217	5290	Wang L	PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.	BMC cancer	2011	50
21822287	5290	Liu P	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.	Nature medicine	2011	88
21829508	5290	Janku F	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.	PloS one	2011	60
22252965	5290	Hernandez L	Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.	The Journal of pathology	2012	40
22271473	5290	Janku F	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.	Journal of clinical oncology 	2012	145
22330809	5290	Cizkova M	PIK3CA mutation impact on survival in breast cancer patients and in ERŒ±, PR and ERBB2-based subgroups.	Breast cancer research 	2012	41
22421194	5290	Higgins MJ	Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.	Clinical cancer research 	2012	56
23092874	5290	Chandarlapaty S	Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.	Clinical cancer research 	2012	43
23532889	5290	Shigaki H	PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.	Clinical cancer research 	2013	28
23739063	5290	Loi S	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.	Journal of the National Cancer Institute	2013	34
23903756	5290	Elkabets M	mTORC1 inhibition is required for sensitivity to PI3K p110Œ± inhibitors in PIK3CA-mutant breast cancer.	Science translational medicine	2013	68
24504125	5290	Beaver JA	Detection of cancer DNA in plasma of patients with early-stage breast cancer.	Clinical cancer research 	2014	34
25199759	5290	Loibl S	PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.	Journal of clinical oncology 	2014	41
25409150	5290	Juric D	Convergent loss of PTEN leads to clinical resistance to a PI(3)KŒ± inhibitor.	Nature	2015	60
25539732	5290	Pestrin M	Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.	Molecular oncology	2015	22
25847936	5290	Isakoff SJ	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.	Journal of clinical oncology 	2015	43
27096951	5290	Elwood PC	Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies.	PloS one	2016	16
9090379	5728	Steck PA	Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.	Nature genetics	1997	558
9467011	5728	Marsh DJ	Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.	Human molecular genetics	1998	118
19729658	5728	Fine B	Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.	Science	2009	79
20533527	5728	McBride KL	Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly.	Autism research 	2010	61
20600018	5728	Heald B	Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers.	Gastroenterology	2010	42
22252256	5728	Tan MH	Lifetime cancer risks in individuals with germline PTEN mutations.	Clinical cancer research 	2012	93
22628410	5728	Martins FC	Evolutionary pathways in BRCA1-associated breast tumors.	Cancer discovery	2012	41
23335809	5728	Bubien V	High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.	Journal of medical genetics	2013	30
24136893	5728	Pilarski R	Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria.	Journal of the National Cancer Institute	2013	41
25190698	5728	Daly MB	Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.	Journal of the National Comprehensive Cancer Network 	2014	30
10446958	5888	Yuan SS	BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.	Cancer research	1999	139
12941707	5888	Shin DS	Full-length archaeal Rad51 structure and mutants: mechanisms for RAD51 assembly and control by BRCA2.	The EMBO journal	2003	102
20400964	5888	Meindl A	Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.	Nature genetics	2010	179
20729832	5888	Jensen RB	Purified human BRCA2 stimulates RAD51-mediated recombination.	Nature	2010	184
22789542	5888	Schlacher K	A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2.	Cancer cell	2012	184
25472942	5888	Sawyer SL	Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.	Cancer discovery	2015	66
24141787	5889	Park JY	Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.	Oncogene	2014	24
18782450	5925	Herschkowitz JI	The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.	Breast cancer research 	2008	86
9771714	6790	Zhou H	Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation.	Nature genetics	1998	306
16707622	6794	Hearle N	Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.	Clinical cancer research 	2006	117
20581245	6794	Beggs AD	Peutz-Jeghers syndrome: a systematic review and recommendations for management.	Gut	2010	66
23535731	7015	Bojesen SE	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.	Nature genetics	2013	181
23610451	7015	Listerman I	The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis.	Cancer research	2013	29
23629941	7015	Pellatt AJ	Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study.	Genes, chromosomes and cancer	2013	28
19345189	7040	Adorno M	A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis.	Cell	2009	250
21189395	7153	Press MF	Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.	Journal of clinical oncology 	2011	48
1849234	7157	Hsu IC	Mutational hotspot in the p53 gene in human hepatocellular carcinomas.	Nature	1991	202
1905840	7157	Hollstein M	p53 mutations in human cancers.	Science	1991	1290
1978757	7157	Malkin D	Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.	Science	1990	522
8423624	7157	Allred DC	Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.	Journal of the National Cancer Institute	1993	132
10766157	7157	Soussi T	p53 Antibodies in the sera of patients with various types of cancer: a review.	Cancer research	2000	117
11830638	7157	Lingle WL	Centrosome amplification drives chromosomal instability in breast tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2002	150
11965534	7157	Mirza A	Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.	Oncogene	2002	130
12649205	7157	Pihan GA	Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas.	Cancer research	2003	102
16141321	7157	Miller LD	An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.	Proceedings of the National Academy of Sciences of the United States of America	2005	509
16170357	7157	Bossi G	Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.	Oncogene	2006	68
16489069	7157	Olivier M	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.	Clinical cancer research 	2006	119
17401424	7157	Petitjean A	TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.	Oncogene	2007	190
17468756	7157	Theodorou V	MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer.	Nature genetics	2007	69
17504517	7157	Langer√∏d A	TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.	Breast cancer research 	2007	93
18094375	7157	Patocs A	Breast-cancer stromal cells with TP53 mutations and nodal metastases.	The New England journal of medicine	2007	93
18685109	7157	Shlien A	Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2008	51
19204208	7157	Gonzalez KD	Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.	Journal of clinical oncology 	2009	86
19308457	7157	Pfeifer GP	Mutational spectra of human cancer.	Human genetics	2009	69
21364938	7157	Enerly E	miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors.	PloS one	2011	115
21779513	7157	Khoury MP	p53 Isoforms: An Intracellular Microprocessor?	Genes and cancer	2011	44
22265415	7157	Freed-Pastor WA	Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.	Cell	2012	163
22715097	7157	Ano Bom AP	Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.	The Journal of biological chemistry	2012	41
22822097	7157	Walerych D	The rebel angel: mutant p53 as the driving oncogene in breast cancer.	Carcinogenesis	2012	61
23151455	7157	Rodriguez OC	Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy.	Cell cycle	2012	33
23649806	7157	Kleiblova P	Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.	The Journal of cell biology	2013	33
24138928	7157	Horvath S	DNA methylation age of human tissues and cell types.	Genome biology	2013	377
24487586	7157	Arjonen A	Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.	The Journal of clinical investigation	2014	36
24658082	7157	Powell E	Contribution of p53 to metastasis.	Cancer discovery	2014	38
25538195	7157	Vieira VC	Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B.	mBio	2014	33
26014290	7157	Bougeard G	Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.	Journal of clinical oncology 	2015	20
25658628	8314	Nasu M	High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.	Journal of thoracic oncology 	2015	31
14638851	8678	Qu X	Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene.	The Journal of clinical investigation	2003	613
19647222	8821	Gewinner C	Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.	Cancer cell	2009	133
21127264	8821	Fedele CG	Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.	Proceedings of the National Academy of Sciences of the United States of America	2010	71
14576842	9429	Doyle L	Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).	Oncogene	2003	156
23852168	9582	Burns MB	Evidence for APOBEC3B mutagenesis in multiple human cancers.	Nature genetics	2013	159
18813315	10000	Davies MA	A novel AKT3 mutation in melanoma tumours and cell lines.	British journal of cancer	2008	93
22722202	10000	Banerji S	Sequence analysis of mutations and translocations across breast cancer subtypes.	Nature	2012	320
24608573	10000	Meric-Bernstam F	Concordance of genomic alterations between primary and recurrent breast cancer.	Molecular cancer therapeutics	2014	21
10426999	10111	Zhong Q	Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.	Science	1999	123
19092773	10111	Ripperger T	Breast cancer susceptibility: current knowledge and implications for genetic counselling.	European journal of human genetics 	2009	45
22006311	10111	Walsh T	Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2011	149
22048815	10111	Weigman VJ	Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.	Breast cancer research and treatment	2012	39
15867337	11186	Agathanggelou A	Role of the Ras-association domain family 1 tumor suppressor gene in human cancers.	Cancer research	2005	108
10617473	11200	Bell DW	Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.	Science	1999	140
11967536	11200	Meijers-Heijboer H	Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.	Nature genetics	2002	216
12094328	11200	Vahteristo P	A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.	American journal of human genetics	2002	86
15122511	11200	CHEK2 Breast Cancer Case-Control Consortium.	CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.	American journal of human genetics	2004	107
15829956	11200	Bartkova J	DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.	Nature	2005	819
16551709	11200	Walsh T	Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.	JAMA	2006	143
24549055	11200	Cast√©ra L	Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.	European journal of human genetics 	2014	39
25186627	11200	Tung N	Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.	Cancer	2015	49
25288723	11200	Kiiski JI	Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	22
26270727	11200	Desmond A	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.	JAMA oncology	2015	24
26483394	11200	Hu C	Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.	Cancer epidemiology, biomarkers and prevention 	2016	11
26976419	11200	Tung N	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.	Journal of clinical oncology 	2016	10
22722193	23451	Ellis MJ	Whole-genome analysis informs breast cancer response to aromatase inhibition.	Nature	2012	283
10786676	51741	Bednarek AK	WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.	Cancer research	2000	104
17287723	79728	Erkko H	A recurrent mutation in PALB2 in Finnish cancer families.	Nature	2007	127
19264984	79728	Jones S	Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.	Science	2009	210
20412113	79728	Slater EP	PALB2 mutations in European familial pancreatic cancer families.	Clinical genetics	2010	68
21285249	79728	Casadei S	Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.	Cancer research	2011	55
16153896	83990	Litman R	BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.	Cancer cell	2005	147
25455730	145270	Duffy MJ	p53 as a target for the treatment of cancer.	Cancer treatment reviews	2014	38
23715497	200315	Xuan D	APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry.	Carcinogenesis	2013	29
25298230	200315	Caval V	A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.	Nature communications	2014	30
